Background: Neutralizing interleukin (IL) 17F in addition to IL-17A might provide a more complete and specific approach to inhibiting inflammation.
Methods: Double-blinded, placebo-controlled phase 2b study (NCT02905006). Patients (randomized 1:1:1:1:1:1) received subcutaneous bimekizumab every 4 weeks at doses of 64 mg, 160 mg, 160 mg with 320 mg loading dose, 320 mg, 480 mg, or placebo. Primary endpoint was $90% reduction in Psoriasis Area Severity Index (PASI90) at week 12.
Results: There was a significant (P \.0001) dose-dependent response for PASI90 (week 12); more patients achieved PASI90 in the bimekizumab groups (46.2%-79.1%) than patients in the placebo group (0%; P \.0001 all doses). Across all doses, there were significant improvements from baseline for all secondary endpoints (PASI90 week 8, PASI75 week 12, PASI100 week 12, and Investigators Global Assessment clear or almost clear weeks 8 and 12; P # .0003) compared with placebo. More bimekizumab-treated patients than placebo-treated patients achieved PASI100 (week 12) (27.9%-60.0% vs 0%; P # .0002 all doses). Treatmentemergent adverse events were reported by 126 of 208 (61%) bimekizumab-treated patients and 15 of 42 (36%) placebo-treated patients. Key words: anti-IL-17; anti-IL-17A; anti-IL-17F; bimekizumab; biologic therapy; clear or almost clear skin; dose ranging; efficacy; interleukin 17A; interleukin 17F; PASI90; PASI100; phase 2b; plaque psoriasis; randomized clinical trial; safety.
Psoriasis is a chronic, immune-mediated inflammatory skin disease that affects up to 3% of the population and is associated with significant comorbidities including chronic pulmonary disease, diabetes, liver disease, cardiovascular disease, chronic kidney disease, and rheumatologic disease. 1, 2 The disease burden extends beyond physical manifestations with significant social and psychologic factors leading to a negative impact on quality of life. 3, 4 Basic immunologic advances augment our understanding of psoriasis pathogenesis and have led to the development of therapies targeted against key proinflammatory cytokines, such as tumor necrosis factor (TNF), interleukin (IL)-17A, and IL-23. 5, 6 While targeting TNF-dependent pathways has demonstrated positive responses in patients with psoriasis, [7] [8] [9] [10] greater efficacy has been achieved with more recently developed drugs that target the IL-23/ T-helper 17 immunologic pathway, a key driver of psoriasis. [11] [12] [13] [14] [15] [16] [17] Despite these advances, achieving completely clear skin and maintaining this level of clearance remains challenging; in addition, several safety considerations have been noted with these therapies, including injection-site reactions, fungal infections (particularly Candida infections), and exacerbations of and new onset inflammatory bowel disease (IBD). [12] [13] [14] 18 Therefore, treatments that demonstrate greater efficacy and fewer safety issues could provide additional patient benefit.
Within the IL-17 cytokine family (IL-17A, IL-17B, IL-17C, IL-17D, IL-17E [also known as IL-25], and IL-17F), the most extensive research has focused on IL-17A. 16, [19] [20] [21] [22] [23] [24] Of the currently available therapies targeting the IL-17 pathway, 2 specifically inhibit IL-17A (secukinumab and ixekizumab), while a third (brodalumab) targets IL-17RA, a receptor subunit used by IL-17A, IL-17C, IL-25, and IL-17F. Although IL-17A and IL-17F are the closest relatives within the IL-17 family, historically, the role of IL-17F has not been widely investigated. IL-17F shares an ;50% structural homology and overlapping biologic proinflammatory function with IL-17A, 20, 25, 26 suggesting it might also play an important role in psoriasis. Indeed, evidence from preclinical studies has
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Growing evidence supports that interleukin (IL) 17F, together with IL-17A, contributes to inflammation. demonstrated that both IL-17A and IL-17F are expressed in lesional skin and inflamed synovium from patients with psoriatic arthritis (PsA).
27-29 Moreover, in preclinical models, both IL-17A and IL-17F have been shown to cooperate with TNF to stimulate production of key proinflammatory cytokines and amplify tissue inflammation.
28,30 When compared with IL-17A blockade alone, dual neutralization of IL-17A and IL-17F resulted in lower levels of expression of inflammation-linked genes and cytokines, as well as a greater suppression of disease-relevant immune cell migration. 27, 28, 30 These data support the rationale for targeting both IL-17A and IL-17F. To that end, bimekizumab, a humanized monoclonal IgG1 antibody, was designed to potently and selectively neutralize the biologic functions of both IL-17A and IL-17F.
Here, we report the efficacy and safety results of a phase 2b dose-ranging study (BE ABLE 1) evaluating bimekizumab (64-480 mg) and placebo in patients with moderate-to-severe plaque psoriasis. The primary objective was to evaluate different doses of bimekizumab administered subcutaneously every 4 weeks for 12 weeks by using the Psoriasis Area and Severity Index (PASI) 90 response (ie, $90% reduction in PASI from baseline readings) at week 12; secondary objectives were to evaluate the efficacy, safety, and tolerability of bimekizumab compared with placebo.
METHODS

Study design and participants
This randomized, double-blinded, placebocontrolled, parallel group, dose-ranging study (NCT02905006) recruited patients during August 25, 2016-March 1, 2017, in 6 countries (Canada, Czech Republic, Hungary, Japan, Poland, and United States). All patients who discontinued or who did not enroll in the extension study (NCT03010527) were required to complete a 20-week safety follow-up visit after administration of the final dose of study drug. The study was conducted in accordance with the principles of the Declaration of Helsinki and the International Conference on Harmonization Guidance for Good Clinical Practice. Independent institutional review board approvals were obtained.
Eligible patients were $18 years of age with a confirmed diagnosis of moderate-to-severe plaque psoriasis for $6 months with a PASI of $12, psoriasis affecting $10% of body surface area, an Investigator's Global Assessment (IGA) score of $3 on a 5-point scale, and who were candidates for systemic psoriasis therapy or phototherapy. Patients were excluded if they had prior treatment with an antieIL-17 therapy or prior exposure to [1 other biologic therapy for psoriasis or PsA, a significant uncontrolled neuropsychiatric disorder, history of a suicide attempt, or suicide ideation within 6 months (assessed using the electronic Columbia Suicide Severity Rating Scale). Other inclusion and exclusion criteria are detailed in the Supplementary Appendix (available at http://www.jaad.org). All patients provided written informed consent in accordance with local requirements.
Patients were randomized (1:1:1:1:1:1) to receive bimekizumab every 4 weeks at doses of 64 mg, 160 mg, 160 mg (with 320 mg loading dose at baseline), 320 mg, 480 mg, or placebo. An interactive voice or web response system was used for assigning eligible patients to a treatment regimen according to a randomization schedule produced by an independent biostatistician who was not associated with the design or analysis of the study. Treatment assignment was stratified by geographic region and prior biologic exposure.
Bimekizumab was provided in single-use vials containing 160 mg/mL. Due to differences in presentation and to ensure study blinding, bimekizumab and placebo injections were prepared and administered at the investigational sites by unblinded, dedicated study personnel (Supplementary Appendix).
Procedures
Treatment was administered at baseline, week 4, and week 8 for a total of 3 subcutaneous injections (Supplementary Appendix). Efficacy and safety were assessed at baseline and weeks 1, 2, 4, 6, 8, and 12. Safety was monitored by an external data monitoring committee.
Outcomes
The primary efficacy endpoint was PASI90 at week 12. Secondary efficacy endpoints were 
Statistical analysis
Analyses of demographics, baseline disease characteristics, and safety included all patients who received a study treatment (safety set). Efficacy analyses included patients who received $1 dose of study treatment and had a valid measurement of the primary efficacy variable at baseline (full analysis set). Sample size calculations were performed based on evaluating a linear dose-response relationship for the proportion of PASI90 responders across ascending doses (0-480 mg bimekizumab). With 40 patients in each treatment group and a 2-sided significance level of 0.05, the test for detecting a linear dose response was powered at [99%.
The primary analysis evaluated the dose-response relationship between treatment and PASI90 response using a logistic regression model, where treatment was included as a linear variable with fixed effects for region and prior biologic exposure (Supplementary Appendix). Patients with missing efficacy data were imputed as nonresponders. Pairwise comparisons of each bimekizumab dose versus placebo for PASI90 at week 12 accounted for multiplicity using a fixed sequence testing procedure, with each bimekizumab dose being tested versus placebo (Fisher's exact test) sequentially from the highest dose to the lowest dose. Subsequent tests were only conducted if the previous test reached significance at a 2-sided significance level of a = 0.05, thereby controlling the overall type I error rate. For secondary endpoints, P values were based on Fisher's exact test (if there were no placebo responders) or the odds ratio from BKZ, Bimekizumab; IGA, Investigator's Global Assessment; LD, loading dose; PASI, Psoriasis Area and Severity Index; PASI75, $75% reduction in PASI from baseline score; PASI90, $90% reduction in PASI from baseline score; PASI100, 100% reduction in PASI from baseline score. a logistic regression model (if there were placebo responders). All P values for secondary endpoints were considered nominal. Safety data were described by using summary statistics.
RESULTS
In this study, 355 patients were screened, with 250 randomized to treatment (Supplemental Figs 1 and 2; available at http://www.jaad.org). Of these, 224 patients completed the study; 26 patients discontinued participation (5 AEs; 1 lack of efficacy; 2 protocol violations; 2 lost to follow-up; 3 withdrew consent; and 13 other reasons). Patient demographics and baseline disease characteristics (Table I) were similar among treatment groups. All randomized patients were included in the full analysis set.
Efficacy
Efficacy increased with dose from placebo to bimekizumab 320 mg (Figs 1 and 2) . A statistically significant dose response was observed for the primary endpoint, PASI90 response at week 12 (P \ .0001). PASI90 response at week 12 was achieved by significantly more patients in all bimekizumab-treatment groups compared with the placebo group (46.2%-79.1% vs 0%; P \ .0001, all comparisons) (Fig 3; Supplemental Figs 3 and 4; available at http://www.jaad.org). The percentage of patients achieving a PASI90 response at week 8 was also significantly greater for each bimekizumab dose compared with placebo (41.0%-86.0% vs 0%; P \ .0001, all comparisons; Supplemental Table I ; available at http://www.jaad.org). A significantly greater percentage of bimekizumab-treated patients achieved PASI75 (61.5%-93.0% vs 4.8%; P \.0001, all comparisons) and PASI100 (27.9%-60.0% vs 0%; P # .0002, all comparisons) at week 12 compared with placebo (Fig 3; Supplemental Fig 3) . When viewed at the individual patient level, there were improvements in absolute PASI over time for patients receiving bimekizumab. By week 12, in the 3 highest dose groups, almost all patients had an absolute PASI \5, with the majority at or near 0 (Fig 2) .
Treatment with bimekizumab was associated with significant improvement from baseline in psoriasis severity compared with placebo, as measured by IGA responders at week 8 (46.2%-86.0% vs 4.8%; P # .0003, all comparisons) and week 12 (51.3%-86.0% vs 4.8%; P # .0001, all comparisons) (Fig 3; Supplemental Table I ). The clinical response was rapid, with clinically meaningful improvements relative to placebo observed in all bimekizumab groups as early as week 4 across all measures of disease activity (Fig 1) .
Safety
The safety set consisted of the 250 patients. Treatment with bimekizumab was not associated with any unexpected safety signals and no doserelated safety risks were observed. Treatmentemergent adverse events (TEAEs) were reported by 126 of 208 (61%) bimekizumab-treated patients and 15 of 42 (36%) placebo-treated patients. The most commonly reported TEAEs ($5% patients in any group) at week 12 are reported in Table II .
AEs led to treatment discontinuation in 10 of 208 (4.8%) bimekizumab-treated patients and 1 of 42 (2.4%) in the placebo group. There was no apparent dose relationship with the incidence of TEAEs leading to discontinuation. Two patients reported 3 serious AEs. Viral meningitis was reported by 1 patient on placebo, and a large intestinal polyp and colon cancer were reported 15 days after the first dose for a patient receiving bimekizumab 480 mg; z P = .0001 for the comparison with placebo. BKZ, Bimekizumab; IGA, Investigator's Global Assessment; LD, loading dose; PASI, Psoriasis Area and Severity Index; PASI75, $75% reduction in PASI from baseline score; PASI90, $90% reduction in PASI from baseline score; PASI100, 100% reduction of PASI from baseline score. both patients were withdrawn from the study. The AE of viral meningitis resolved. None of the serious AEs were considered related to the study treatment by the investigator. No deaths were reported during the study.
Fungal infections (oral candidiasis, oral fungal infection, vulvovaginal mycotic infection, and tinea pedis) were reported in 9 (4.3%) bimekizumabtreated patients (Supplemental Table II ; available at http://www.jaad.org); no cases were reported in the placebo group. No cases of anaphylactic reactions, IBD, major cardiovascular events, neuropsychiatric events, serious hematopoietic cytopenias, or systemic opportunistic infections were reported during the treatment period. Five patients receiving bimekizumab had grade 2 nonserious neutropenia, all of which were transient and resolved without interruption of study treatment.
DISCUSSION
In this phase 2b study, bimekizumab treatment of moderate-to-severe psoriasis was associated with superior efficacy versus placebo in all primary and secondary endpoints. The highest responses were generally observed in the 320 mg dose group, with ;80% of patients achieving high levels of skin clearance (PASI90 or IGA clear or almost clear) at week 12. Of note, around 50%-60% of patients in the 3 highest dose groups achieved complete skin clearance (PASI100) at week 12. The rapid onset of clinically meaningful skin clearance was notable, with PASI75 response rates of 70%-80%, occurring in the bimekizumab 160 mg with 320 mg loading dose, 320 mg, and 480 mg groups as early as week 4, after a single dose of bimekizumab. Although it appears that the dose response peaked at bimekizumab 320 mg, with numerically lower responses seen in the 480 mg dose group, the small patient numbers and short duration of the study do not enable us to determine from these data alone whether this observation illustrates saturation of the doseresponse curve, variability in disease biology among patients, or variability in assessments.
In a first-in-human single-dose study in patients with mild psoriasis (NCT02529956), bimekizumab treatment was associated with rapid onset of clinically meaningful efficacy and sustained reductions in disease activity measures, with no unexpected safety signals. 31 A subsequent phase 1b proof-of-concept study in patients with PsA (NCT02141763) did not identify any new safety signals, and met both predefined efficacy criteria, demonstrating superiority of bimekizumab over both placebo and a predefined clinically relevant threshold (based on results from a TNF inhibitor clinical study) as assessed by American College of Rheumatology response rates at week 8. 32 Moreover, in patients with skin involvement (body surface area $3%), week 8 response rates for PASI75 and PASI100 were 100% and 87%, respectively, compared with 0% for placebo. Overall, the results from the current study in patients with moderate-to-severe psoriasis further build on the encouraging outcomes observed in the early clinical trials of bimekizumab and support the preclinical evidence that IL-17F plays a meaningful role in chronic tissue inflammation, beyond that of IL-17A.
Although it is not possible to draw conclusions from comparisons across clinical studies in the absence of direct head-to-head data, the magnitude and particularly the speed at which high levels of skin clearance were achieved in the current trial appear to compare favorably to therapies targeting IL-17A alone, 11, 12 the IL-17RA subunit, 13, 14 or IL-23. [15] [16] [17] Future analyses and phase 3 clinical trials with active comparators with different mechanisms of action will help characterize the net contribution of IL-17F neutralization to potentially improve outcomes across different disease manifestations.
Overall, TEAEs occurred with greater frequency in patients treated with bimekizumab than those receiving placebo. Although the study was 12 weeks in duration, the safety profile was consistent with previous reports 31, 32 and there were no unexpected clinically relevant safety findings. Reported AEs were generally mild to moderate in intensity and resolved; there was no relationship between increased dose and AEs (type or frequency). The nonserious neutropenia cases reported were transient and resolved without interruption of the study treatment. Trials of longer duration are required to fully establish the safety profile of bimekizumab.
Consistent with the association between therapies targeting the IL-17 pathway and increased susceptibility to mucocutaneous fungal infections, 33,34 9 fungal infections (4 of which were oral candidiasis) were reported during the treatment period across bimekizumab dose groups, with no association between events and dose. All cases were localized, superficial infections of mild or moderate intensity and none led to discontinuation. In the context of previous reports with anti-IL-17A and anti-IL-17RA antibodies, [12] [13] [14] 18 the absence of anaphylactic reactions, IBD, neuropsychiatric events or systemic opportunistic infections is promising, although it must be noted that the present study was only 12 weeks in duration and evaluated 250 patients.
Indeed, the interpretation of the results is limited by small sample size and short treatment duration, which are both inherent to phase 2 studies. Larger studies of longer duration are needed to fully evaluate the efficacy and safety of bimekizumab in this population.
In conclusion, these 12-week phase 2b data provide encouraging evidence that dual neutralization of IL-17A and IL-17F with bimekizumab can provide both rapid and complete skin clearance in a majority of patients with moderate-to-severe plaque psoriasis and suggest it may be a new therapeutic approach in this population. 
SUPPLEMENTARY APPENDIX INCLUSION CRITERIA
Patients were eligible to participate in this study if all the following criteria were met at screening and reconfirmed at the baseline visit: d They were at least 18 years of age. 
EXCLUSION CRITERIA
Patients were not permitted to enroll in the study if any of the following criteria were met: d They were female patients who were breastfeeding, pregnant, or planned to become pregnant during the study or within 20 weeks after last dose of study drug. They were male patients who were planning to impregnate their partners during the study or within 20 weeks after the last dose. d They previously participated in a bimekizumab clinical trial or another study of a medication or a medical device under investigation within the past 3 months or at least 5 half-lives, whichever was greater, or were currently participating in another study of a medication or medical device under investigation. d They had a known hypersensitivity to any excipients of bimekizumab. d They had an erythrodermic, guttate, pustular form of psoriasis or drug-induced psoriasis. d They had a history of chronic or recurrent infections, or a serious or life-threatening infection within the 6 months before the baseline visit (including herpes zoster).
d They had a high risk for infection in the investigator's opinion, any current sign or symptom that may have indicated an active infection (except for common cold), or an infection requiring systemic antibiotics within 2 weeks of baseline. d They had concurrent acute or chronic viral hepatitis B or C or HIV infection. d They had a known history of or current clinically active infection with Histoplasma, Coccidiodes, Paracoccidioides, Pneumocystis, nontuberculous mycobacteria, Blastomyces or Aspergillus, or current active candidiasis (local or systemic). d They had live (including attenuated) vaccination within the 8 weeks before baseline, or Bacillus Calmette-Guerin (BCG) vaccinations within 1 year before study drug administration. Live vaccines were not allowed during the study or for 20 weeks after the last dose of study drug. d They had a history of a lymphoproliferative disorder, including lymphoma or current signs and symptoms suggestive of lymphoproliferative disease. d They had primary immunosuppressive conditions, including immunosuppressive therapy following an organ transplant. d They had a known tuberculosis (TB) infection, were at high risk of acquiring TB infection, had a latent TB infection, or current or history of nontuberculous mycobacterial infection. d They had a splenectomy. d They had concurrent malignancy or history of malignancy (including surgically resected uterine or cervical carcinoma in situ) during the past 5 years. However, the following conditions might have been included: #3 excised or ablated basal cell carcinomas of the skin; 1 squamous cell carcinoma of the skin (stage T1 maximum) successfully excised or ablated only with no signs of recurrence or metastases for [2 years before screening; actinic keratoses; and squamous cell carcinoma in situ of the skin successfully excised or ablated [6 months before screening. d They had major surgery (including joint surgery) within the 6 months before screening, or planned surgery within 6 months after entering the study. d They had current or recent history, as determined by the investigator, of severe, progressive, or uncontrolled renal, hepatic, hematologic, endocrine, pulmonary, cardiac, gastrointestinal, or neurological disease. than the ULN total bilirubin (or $1.5 x ULN total bilirubin if known to have Gilbert syndrome). d They had clinically significant laboratory abnormalities (eg, creatinine [1.5 x ULN, neutropenia \1.5 3 10 9 /L, hemoglobin \8.5 g/dL, lymphocytes \1.0 3 10 9 /L, platelets \100 3 10 9 /L). 
ADDITIONAL DETAILS OF BLINDING
1. Bimekizumab was provided in single-use vials containing 160 mg/mL. Placebo was supplied as 0.9% saline solution. Treatments were administered as 3 subcutaneous injections (lateral abdominal wall and upper outer thigh). During each dosing visit, each of the 3 injections was administered at a separate injection site, and sites were rotated. Due to differences in presentation and to ensure study blinding, bimekizumab and placebo injections were prepared and administered at the investigational sites by unblinded, dedicated study personnel. The unblinded personnel were not involved in the study in any way other than assuring the medication was taken from the correct kit and administered to patients. All other study personnel remained blinded and did not have access to medication-related information. To preserve the blinding of treatment doses, each administration consisted of 3 subcutaneous injections (Supplemental Table III ).
ADDITIONAL DETAILS OF PRIMARY ANALYSIS
The prespecified logistic regression model for the primary analysis of evaluating a linear dose response defined fixed effects for treatment group, region, and prior biologic exposure. However, because there were no PASI90 responders in the placebo group, this model did not converge. Therefore, the model was modified such that treatment was specified as a linear predictor (rather than a class variable) where placebo, bimekizumab 64 mg, 160 mg, 320 mg, and 480 mg every 4 weeks were assigned numeric values of À2, À1, 0, 1, and 2, respectively. The 160 mg (with 320 mg loading dose at baseline) dose was not included in the primary logistic regression model to evaluate dose response.
Pairwise comparisons between each dose of bimekizumab and placebo were planned to be based on a logistic regression model including fixed effects for treatment, region, and prior biologic exposure. However, due to the lack of PASI90 or PASI100 responders in the placebo group, all pairwise comparisons for these variables were based on Fisher's exact test instead of logistic regression. For IGA at weeks 8 and 12, as well as PASI75 at week 12, P values for the pairwise comparisons were based on the odds ratios from the logistic regression model as originally planned. The model estimates for the primary logistic regression model that were used to evaluate the dose response are provided in Supplemental Table IV . Supplemental Table II Adverse events of interest were identified by UCB for special monitoring. An adverse event of interest was defined as an adverse event or safety topic for which special monitoring, additional data collection activities, or enhanced signal detection activities were considered appropriate, based on findings from the clinical program to date, potential risks generally associated with biologic immunomodulators, or comorbidities and risk factors prevalent in the study population.
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